Neoleukin Therapeutics, Inc. (NASDAQ:NLTX – Get Free Report) shares shot up 1.7% on Monday . The company traded as high as $39.44 and last traded at $38.63. Approximately 346,580 shares changed hands during mid-day trading, an increase of 592% from the average session volume of 50,104 shares. The stock had previously closed at $37.99.
Neoleukin Therapeutics Stock Performance
The firm has a 50 day simple moving average of $34.98 and a two-hundred day simple moving average of $27.60. The firm has a market capitalization of $363.04 million, a P/E ratio of -12.42 and a beta of 1.11.
About Neoleukin Therapeutics
Neoleukin Therapeutics, Inc is a clinical?stage biotechnology company focused on the design and development of de novo protein therapeutics for the treatment of cancer and immune?mediated diseases. Leveraging computational protein engineering, the company creates novel cytokine mimetics intended to provide targeted immune activation while minimizing the toxicities associated with natural cytokines. This platform is anchored by proprietary algorithms and structure?based design tools that enable the rapid generation of therapeutic candidates with optimized stability, affinity and specificity.
The company’s lead candidate, NL-201, is a next?generation cytokine therapy designed to engage interleukin?2 and interleukin?15 receptors on immune effector cells, with the goal of enhancing anti?tumor responses.
Featured Stories
- Five stocks we like better than Neoleukin Therapeutics
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
